{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:32:53Z","timestamp":1793406773567,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["19401972300"],"award-info":[{"award-number":["19401972300"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["2021CXGC010509"],"award-info":[{"award-number":["2021CXGC010509"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"State Administration of Traditional Chinese Medicine of the People's Republic of China","doi-asserted-by":"publisher","award":["2017-124"],"award-info":[{"award-number":["2017-124"]}],"id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases and has become a huge public health issue worldwide. Inhibition of nucleotide oligomerization domain-like receptors containing pyrin domain 3 (NLRP3) inflammasome is a potential therapeutic strategy for NAFLD. Currently, there are no drugs targeting NLRP3 inflammasome for clinical treatment of NAFLD. In this study, we explored the efficacy and mechanism of rhubarb free anthraquinones (RFAs) in treating NAFLD by inhibiting NLRP3 inflammasome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>First, NLRP3 inflammasome was established in mouse bone marrow-derived macrophages (BMDMs), Kuffer cells and primary hepatocytes stimulated by lipopolysaccharide (LPS) and inflammasome inducers to evaluate the effect of RFAs on inhibiting NLRP3 inflammasome and explore the possible mechanism. Further, Mice NAFLD were established by methionine and choline deficiency diet (MCD) to verify the effect of RFAs on ameliorating NAFLD by inhibiting NLRP3 inflammasome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our results demonstrated that RFAs including rhein\/diacerein, emodin, aloe emodin and 1,8-dihydroxyanthraquinone inhibited interleukin-1 beta (IL-1\u03b2) but had no effect on tumor necrosis factor-alpha (TNF-\u03b1). Similar results were also showed in mouse primary hepatocytes and Kuffer cells. RFAs inhibited cleavage of caspase-1, formation of apoptosis-associated speck-like protein containing a CARD (ASC) speck, and the combination between NLRP3 and ASC. Moreover, RFAs improved liver function, serum inflammation, histopathological inflammation score and liver fibrosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>RFAs including rhein\/diacerein, emodin, aloe emodin and 1,8-dihydroxyanthraquinone ameliorated NAFLD by inhibiting NLRP3 inflammasome. RFAs might be a potential therapeutic agent for NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12967-022-03495-4","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T10:16:59Z","timestamp":1656411419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Rhubarb free anthraquinones improved mice nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome"],"prefix":"10.1186","volume":"20","author":[{"given":"Chao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisma Lena Bahaji","family":"Azami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8103-7283","authenticated-orcid":false,"given":"Mingyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"issue":"21","key":"3495_CR1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","volume":"377","author":"AM Diehl","year":"2017","unstructured":"Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377(21):2063\u201372.","journal-title":"N Engl J Med"},{"issue":"4","key":"3495_CR2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/hep.28584","volume":"64","author":"A Lonardo","year":"2016","unstructured":"Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, Targher G. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(4):1388\u20139.","journal-title":"Hepatology"},{"issue":"6","key":"3495_CR3","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611\u201325.","journal-title":"Gastroenterology"},{"issue":"7","key":"3495_CR4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851\u201364.","journal-title":"Gastroenterology"},{"issue":"10","key":"3495_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/SMJ.0b013e3181b5771d","volume":"102","author":"DS Bell","year":"2009","unstructured":"Bell DS. The association of obesity, metabolic syndrome, diabetes, and cardiovascular disease with nonalcoholic fatty liver disease. South Med J. 2009;102(10):991\u20132.","journal-title":"South Med J"},{"issue":"5","key":"3495_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/jgh.13264","volume":"31","author":"S Ballestri","year":"2016","unstructured":"Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936\u201344.","journal-title":"J Gastroenterol Hepatol"},{"key":"3495_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/endrev\/bnz009","volume":"41","author":"T Marjot","year":"2020","unstructured":"Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr Rev. 2020;41:1.","journal-title":"Endocr Rev"},{"issue":"8","key":"3495_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"3495_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1001\/jama.2020.10434","volume":"324","author":"MM Grajower","year":"2020","unstructured":"Grajower MM. Nonalcoholic Steatohepatitis. JAMA. 2020;324(9):899.","journal-title":"JAMA"},{"issue":"4","key":"3495_CR10","first-page":"197","volume":"14","author":"H Thomas","year":"2017","unstructured":"Thomas H. NAFLD: A critical role for the NLRP3 inflammasome in NASH. Nat Rev Gastroenterol Hepatol. 2017;14(4):197.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"3495_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.tcb.2017.05.005","volume":"27","author":"SB Kovacs","year":"2017","unstructured":"Kovacs SB, Miao EA. Gasdermins: effectors of pyroptosis. Trends Cell Biol. 2017;27(9):673\u201384.","journal-title":"Trends Cell Biol"},{"issue":"5","key":"3495_CR12","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66(5):1037\u201346.","journal-title":"J Hepatol"},{"issue":"1","key":"3495_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/imr.12908","volume":"297","author":"D Chauhan","year":"2020","unstructured":"Chauhan D, Vande Walle L, Lamkanfi M. Therapeutic modulation of inflammasome pathways. Immunol Rev. 2020;297(1):123\u201338.","journal-title":"Immunol Rev"},{"issue":"8","key":"3495_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3495_CR15","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","volume":"9","author":"H He","year":"2018","unstructured":"He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, Liu Q, Liang G, Deng X, Jiang W, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9(1):2550.","journal-title":"Nat Commun"},{"issue":"3","key":"3495_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248\u201355.","journal-title":"Nat Med"},{"issue":"7","key":"3495_CR17","doi-asserted-by":"publisher","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","volume":"115","author":"C Marchetti","year":"2018","unstructured":"Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, Carta S, Tengesdal I, Nemkov T, D\u2019Alessandro A, et al. OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci U S A. 2018;115(7):E1530\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3495_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.15252\/emmm.201708689","volume":"10","author":"Y Huang","year":"2018","unstructured":"Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, Deng X, Liang G, Zhang H, Jiang W, et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. 2018;10:4.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"3495_CR19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.immuni.2021.05.004","volume":"54","author":"H Xian","year":"2021","unstructured":"Xian H, Liu Y, Rundberg Nilsson A, Gatchalian R, Crother TR, Tourtellotte WG, Zhang Y, Aleman-Muench GR, Lewis G, Chen W, et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. 2021;54(7):1463\u201377.","journal-title":"Immunity"},{"issue":"3","key":"3495_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/joca.1999.0289","volume":"8","author":"F Moldovan","year":"2000","unstructured":"Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage. 2000;8(3):186\u201396.","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"3495_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1142\/S0192415X19500071","volume":"47","author":"WC Chang","year":"2019","unstructured":"Chang WC, Chu MT, Hsu CY, Wu YJ, Lee JY, Chen TJ, Chung WH, Chen DY, Hung SI. Rhein, An Anthraquinone Drug, Suppresses the NLRP3 inflammasome and macrophage activation in urate crystal-induced gouty inflammation. Am J Chin Med. 2019;47(1):135\u201351.","journal-title":"Am J Chin Med"},{"key":"3495_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13020-017-0158-5","volume":"12","author":"YJ Cao","year":"2017","unstructured":"Cao YJ, Pu ZJ, Tang YP, Shen J, Chen YY, Kang A, Zhou GS, Duan JA. Advances in bio-active constituents, pharmacology and clinical applications of rhubarb. Chin Med. 2017;12:36.","journal-title":"Chin Med"},{"key":"3495_CR23","first-page":"36","volume":"12","author":"YJ Cao","year":"2017","unstructured":"Cao YJ. Advances in bio-active constituents, pharmacology and clinical applications of rhubar. BChen. 2017;12:36.","journal-title":"BChen"},{"issue":"7","key":"3495_CR24","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3748\/wjg.v23.i7.1125","volume":"23","author":"JY Li","year":"2017","unstructured":"Li JY, Cao HY, Sun L, Sun RF, Wu C, Bian YQ, Dong S, Liu P, Sun MY. Therapeutic mechanism of Yin-Chen-Hao decoction in hepatic diseases. World J Gastroenterol. 2017;23(7):1125\u201338.","journal-title":"World J Gastroenterol"},{"key":"3495_CR25","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3389\/fimmu.2015.00570","volume":"6","author":"AJ Greaney","year":"2015","unstructured":"Greaney AJ, Leppla SH, Moayeri M. Bacterial Exotoxins and the Inflammasome. Front Immunol. 2015;6:570.","journal-title":"Front Immunol"},{"issue":"6","key":"3495_CR26","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","volume":"38","author":"R Munoz-Planillo","year":"2013","unstructured":"Munoz-Planillo R, Kuffa P, Martinez-Colon G, Smith BL, Rajendiran TM, Nunez G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38(6):1142\u201353.","journal-title":"Immunity"},{"issue":"8","key":"3495_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/ni.1631","volume":"9","author":"V Hornung","year":"2008","unstructured":"Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847\u201356.","journal-title":"Nat Immunol"},{"issue":"3","key":"3495_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.immuni.2012.01.009","volume":"36","author":"K Shimada","year":"2012","unstructured":"Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, Ramanujan VK, Wolf AJ, Vergnes L, Ojcius DM, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36(3):401\u201314.","journal-title":"Immunity"},{"issue":"5","key":"3495_CR29","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1084\/jem.20150237","volume":"214","author":"L Freeman","year":"2017","unstructured":"Freeman L, Guo H, David CN, Brickey WJ, Jha S, Ting JP. NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J Exp Med. 2017;214(5):1351\u201370.","journal-title":"J Exp Med"},{"issue":"1","key":"3495_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.smim.2003.10.003","volume":"16","author":"K Takeda","year":"2004","unstructured":"Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004;16(1):3\u20139.","journal-title":"Semin Immunol"},{"key":"3495_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.arr.2017.02.004","volume":"36","author":"M Rahimifard","year":"2017","unstructured":"Rahimifard M, Maqbool F, Moeini-Nodeh S, Niaz K, Abdollahi M, Braidy N, Nabavi SM, Nabavi SF. Targeting the TLR4 signaling pathway by polyphenols: A novel therapeutic strategy for neuroinflammation. Ageing Res Rev. 2017;36:11\u20139.","journal-title":"Ageing Res Rev"},{"key":"3495_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-981-10-8684-7_3","volume":"1061","author":"GC Farrell","year":"2018","unstructured":"Farrell GC, Haczeyni F, Chitturi S. Pathogenesis of NASH: how metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease. Adv Exp Med Biol. 2018;1061:19\u201344.","journal-title":"Adv Exp Med Biol"},{"key":"3495_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.643149","volume":"12","author":"WJ Zhang","year":"2021","unstructured":"Zhang WJ, Chen SJ, Zhou SC, Wu SZ, Wang H. Inflammasomes and fibrosis. Front Immunol. 2021;12: 643149.","journal-title":"Front Immunol"},{"key":"3495_CR34","first-page":"44","volume":"89","author":"IV Hochheiser","year":"2022","unstructured":"Hochheiser IV, Pilsl M, Hagelueken G, Moecking J, Marleaux M, Brinkschulte R, Latz E, Engel C, Geyer M. Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature. 2022;89:44.","journal-title":"Nature"},{"issue":"4","key":"3495_CR35","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.18632\/aging.203907","volume":"14","author":"H Li","year":"2022","unstructured":"Li H, Guo Z, Chen J, Du Z, Lu H, Wang Z, Xi J, Bai Y. Computational research of Belnacasan and new Caspase-1 inhibitor on cerebral ischemia reperfusion injury. Aging (Albany NY). 2022;14(4):1848\u201364.","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"3495_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0168-8278(03)00005-9","volume":"38","author":"VJ Desmet","year":"2003","unstructured":"Desmet VJ, Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431\u2013435]. J Hepatol. 2003;38(4):382\u20136.","journal-title":"J Hepatol"},{"key":"3495_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-62703-523-1_8","volume":"1040","author":"A Stutz","year":"2013","unstructured":"Stutz A, Horvath GL, Monks BG, Latz E. ASC speck formation as a readout for inflammasome activation. Methods Mol Biol. 2013;1040:91\u2013101.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"3495_CR38","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jhep.2012.03.035","volume":"57","author":"G Szabo","year":"2012","unstructured":"Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol. 2012;57(3):642\u201354.","journal-title":"J Hepatol"},{"issue":"1","key":"3495_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nri.2015.7","volume":"16","author":"SM Man","year":"2016","unstructured":"Man SM, Kanneganti TD. Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat Rev Immunol. 2016;16(1):7\u201321.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"3495_CR40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41422-020-0295-8","volume":"30","author":"S Christgen","year":"2020","unstructured":"Christgen S, Place DE, Kanneganti TD. Toward targeting inflammasomes: insights into their regulation and activation. Cell Res. 2020;30(4):315\u201327.","journal-title":"Cell Res"},{"issue":"3","key":"3495_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41577-019-0228-2","volume":"20","author":"P Broz","year":"2020","unstructured":"Broz P, Pelegrin P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020;20(3):143\u201357.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"3495_CR42","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/hep.26592","volume":"59","author":"A Wree","year":"2014","unstructured":"Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, Hoffman HM, Feldstein AE. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59(3):898\u2013910.","journal-title":"Hepatology"},{"issue":"3","key":"3495_CR43","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.28456","volume":"64","author":"H Tilg","year":"2016","unstructured":"Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Hepatology. 2016;64(3):955\u201365.","journal-title":"Hepatology"},{"issue":"2","key":"3495_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nri3793","volume":"15","author":"AR Tall","year":"2015","unstructured":"Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104\u201316.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"3495_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"3495_CR46","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jhep.2020.04.001","volume":"73","author":"J Gautheron","year":"2020","unstructured":"Gautheron J, Gores GJ, Rodrigues CMP. Lytic cell death in metabolic liver disease. J Hepatol. 2020;73(2):394\u2013408.","journal-title":"J Hepatol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03495-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03495-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03495-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T22:05:56Z","timestamp":1666389956000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03495-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3495"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03495-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}